Introduction
============

Spindle cell tumors are clinically heterogeneous but morphologically similar neoplasms that can occur anywhere. The term is descriptive and based on the tumor cells\' long and slender microscopic appearance (<https://librepathology.org/wiki/Spindle_cell_lesions>). The diagnosis of spindle cell tumors relies on histological and morphological features supported by ancillary investigations which include immunohistochemistry, cytogenetics, fluorescence *in situ* hybridization (FISH), and/or molecular genetics. The diagnosis is prognostically imprecise and even sometimes fails to distinguish benign from low-grade malignant tumors ([@b1-or-37-06-3181],[@b2-or-37-06-3181]).

Cytogenetic and molecular genetic analyses of spindle cell tumors have led to the recognition of several distinct karyotypic entities, presumably corresponding to equally distinct pathogenetic subgroups, characterized by chromosomal translocations and also fusion genes that identify specific tumor types ([@b3-or-37-06-3181]). For example, congenital fibrosarcomas carry the translocation t(12;15)(p13;q25) which results in the generation of an *ETV6-NTRK3* fusion gene ([@b4-or-37-06-3181]). Dermatofibrosarcoma protuberans, another subtype of spindle cell sarcoma, is characterized cytogenetically by supernumerary ring chromosomes or the translocation t(17;22)(q22;q13) ([@b5-or-37-06-3181]). Either change results in formation of a *COL1A1-PDGFB* fusion gene in which *PDGFB* exon 1 is deleted and replaced by a variable segment of the *COL1A1* gene ([@b5-or-37-06-3181]). A subset of inflammatory myofibroblastic tumor, a neoplasm composed of myofibroblastic spindle cells and infiltrating inflammatory cells, harbor clonal chromosomal rearrangements of chromosome band 2p23 ([@b6-or-37-06-3181]). These rearrangements target the *ALK* gene which may serve as the 3′-partner in fusions with various translocation partners bringing about ALK tyrosine kinase activation ([@b6-or-37-06-3181]).

Solitary fibrous tumor, another rare spindle cell tumor, is now defined genetically as carrying a submicroscopic inversion of the long arm of chromosome 12 (12q13) resulting in fusion of the two neighboring genes *NAB2* and *STAT6* ([@b7-or-37-06-3181]--[@b10-or-37-06-3181]). This creates a chimeric transcription factor in which the NAB2 repressor domain is substituted by a carboxyl-terminal STAT6 transactivation domain or near-full-length *STAT6* ([@b7-or-37-06-3181]--[@b10-or-37-06-3181]).

In spite of all these genetic-pathologic correlations, other spindle cell tumors exist that have not yet been found to have characteristic, let alone pathognomonic, genetic or pathogenetic features. By way of example, Fruth *et al* ([@b11-or-37-06-3181]) reported a laryngeal spindle cell sarcoma which did not fit into any of the existing spindle cell sarcoma sub-entities: The initially benign-appearing mesenchymal tumor first changed its clinical phenotype without corresponding histological signs of malignancy but later assumed more aggressive histological features. Alaggio *et al* ([@b12-or-37-06-3181]) described two spindle cell tumors with *EWSR1-WT1* fusion and favorable prognosis. According to the authors, the tumors could represent 'an unrecognized subgroup of tumors with spindle cell morphology, bearing the same translocation as desmoplastic small round cell tumor, but characterized by a more favorable clinical course'. In a previous study of ours, we described a spindle cell sarcoma that could not be further sub-classified, but which carried a ring chromosome composed of chromosome 12 material, several fusion genes mapping to 12q, and amplification of *MDM2* ([@b13-or-37-06-3181]). Nord *et al* ([@b14-or-37-06-3181]) reported a spindle cell sarcoma of the heart with a ring chromosome, amplification of the *MDM2* gene, and homozygous deletion of *CDKN2A*. Finally, Lestou *et al* ([@b15-or-37-06-3181]) reported a case of spindle cell sarcoma in the lower abdominal wall with a complex karyotype, ring chromosomes, amplification of chromosome 18, and co-amplification of 12p11 and 12q13-q22 in the ring chromosomes. The examples above show that continuous examination of tumors with spindle cell morphology is likely to reveal yet other genetic subgroups that may, in the future, be seen to correspond to meaningful clinical and even, when suitable therapeutics are construed against the pathogenetic mechanisms involved, be also therapeutically decisive.

In the present study, we analyzed genetically a pediatric spindle cell tumor. The cytogenetic analysis showed that the tumor cells carried a t(3;17)(p21;q12) chromosomal translocation and RNA sequencing identified a *SETD2-NF1* fusion gene caused by the translocation.

Materials and methods
=====================

### Ethics statement

The study was approved by the Regional Committee for Medical and Health Research Ethics, South-East Norway (REK sør-øst; <http://helseforskning.etikkom.no>) and written informed consent was obtained from the patient for publication of the case details. The ethics committee\'s approval included a review of the consent procedure. All patient information has been de-identified.

### Case history

A 16-year-old male presented with a mass in the left deltoid region. After analysis of a needle biopsy, surgical resection was performed. Macroscopic examination disclosed a 4.2 cm large, well demarcated tumor ([Fig. 1A](#f1-or-37-06-3181){ref-type="fig"}). Microscopic examination revealed a moderately cellular tumor with spindle cells without clear atypia intermingled with loose intercellular matrix, partly with myxoid tissue and collagen ([Fig. 1B](#f1-or-37-06-3181){ref-type="fig"}). Dilated vessels were seen. There were some necrotic areas but very few mitotic figures (0--1/10 high power fields). Immunohistochemistry demonstrated positive focal staining for CD34 and CD99 ([Fig. 1C and D](#f1-or-37-06-3181){ref-type="fig"}), but negativity for cytokeratin cocktail (AE1/AE3, EMA, S-100, SMA, and desmin; data not shown). There was no nuclear STAT6 staining and the molecular analysis did not show presence of the *NAB2-STAT6* fusion transcript which is pathognomonic for solitary fibrous tumor. FISH analysis was negative for rearrangement of the *FUS* gene. The histological diagnosis could therefore not be more precise than spindle cell tumor of uncertain malignancy. Three years after treatment, no local recurrence has developed and the patient is in remission.

### G-banding and karyotyping

Both a core needle preoperative biopsy and fresh tissue from a representative area of the tumor in the surgical specimen were received and analyzed cytogenetically as part of our diagnostic routine. The samples were disaggregated mechanically and enzymatically with collagenase II (Worthington, Freehold, NJ, USA). The resulting cells were cultured and harvested using standard techniques ([@b16-or-37-06-3181]). Chromosome preparations were G-banded with Wright stain and examined. The karyotype was written according to The International System for Human Cytogenetic Nomenclature (ISCN) 2013 guidelines ([@b17-or-37-06-3181]).

### High-throughput paired-end RNA-sequencing analysis

Tumor tissue adjacent to that used for cytogenetic analysis and histologic examination was frozen and stored at −80°C. Total RNA was extracted using miRNeasy Mini kit according to the manufacturer\'s instructions (Qiagen Nordic, Oslo, Norway). Tumor tissue was disrupted and homogenized in Qiazol Lysis Reagent (Qiagen Nordic) using a 5 mm stainless steel bead and TissueLyser II (Qiagen Nordic). Subsequently, total RNA was purified using QIAcube (Qiagen Nordic). The RNA quality was evaluated using the Experion Automated Electrophoresis System (Bio-Rad Laboratories, Oslo, Norway). The RNA quality indicator (RQI) was 9.9. Total RNA (3 µg) was sent for high-throughput paired-end RNA-sequencing at the Norwegian Sequencing Centre, Ullevål Hospital (<http://www.sequencing.uio.no/>). Detailed information about the high-throughput paired-end RNA-sequencing was given elsewhere ([@b18-or-37-06-3181]). The software FusionCatcher ([@b19-or-37-06-3181]) (<https://github.com/ndaniel/fusioncatcher>) was used for discovery of fusion transcripts.

### Molecular genetic analysis

Total RNA (1 µg) was reverse-transcribed in a 20 µl reaction volume using iScript Advanced cDNA Synthesis kit for RT-qPCR according to the manufacturer\'s instructions (Bio-Rad Laboratories). The 25 µl PCR volume contained 12.5 µl Premix Ex Taq DNA Polymerase Hot Start version (Takara Bio Europe/SAS, Saint-Germain-en-Laye, France), 2 µl of cDNA, and 0.4 µM of each of the forward primer SETD2-7227F1 (5′-CCTCCCAACTGGAAGACAGCTCGA-3′) and reverse primer NF1-020-452R1 (5′-AGCTTTCCAACCCAGGACTGTGGTC-3′). The PCR was run on a C-1000 Thermal cycler (Bio-Rad Laboratories). The PCR conditions for amplification were: initial denaturation at 94°C for 30 sec followed by 35 cycles of 7 sec at 98°C and 2 min at 68°C, and a final extension for 5 min at 68°C. PCR products (3 µg) were stained with GelRed (Biotium), analyzed by electrophoresis through 1.0% agarose gel, and photographed. The remaining 22 µl PCR products were purified using the MinElute PCR purification kit (Qiagen Nordic) and direct sequenced using the light run sequencing service of GATC Biotech (<http://www.gatc-biotech.com/en/sanger-services/lightrun-sequencing.html>). The BLAST software (<http://www.ncbi.nlm.nih.gov/BLAST/>) was used for computer analysis of sequence data.

### Fluorescence in situ hybridization (FISH)

BAC probes were retrieved from the Human '32K' BAC Re-Array library (BACPAC Resources, <http://bacpac.chori.org/home.htm>). They were selected according to physical and genetic mapping data on chromosomes 3 and 17 (see below) as reported on the Human Genome Browser at the University of California, Santa Cruz website (May 2004, <http://genome.ucsc.edu/>). FISH mapping of the clones on normal controls was performed to confirm their chromosomal location. The clones were RP11-565B06 (chr3:46962826-47104129) and RP11-380M12 (chr3:47033474-47226748) mapping to chromosome subband 3p21.31 which contains the *SETD2* gene (red signal), and RP11-518B17 (chr17:26576215-26749754) and RP11-592F3 (chr17:26705272-26874157) mapping to chromosome subband 17q11.2 which contains the *NF1* gene (green signal). FISH was performed as described elsewhere ([@b18-or-37-06-3181]). Fluorescent signals were captured and analyzed using the CytoVision system (Leica Biosystems, Newcastle, UK).

Results
=======

### G-banding

The G-banding analysis of short-term cultured cells from both the core needle biopsy and surgical specimen yielded the karyotype 46,XY,t(3;17)(p21;q12),del(10)(q24)\[11\] ([Fig. 2A](#f2-or-37-06-3181){ref-type="fig"}).

### RNA-sequencing, molecular genetic analysis, and FISH confirmation of SETD2-NF1 fusion

Using the FusionCatcher software with the fastq files obtained from the Norwegian Sequencing Centre, 31 potential fusion transcripts were found ([Table I](#tI-or-37-06-3181){ref-type="table"}), among them *SETD2-NF1*. Taking into consideration that *SETD2* and *NF1* map to chromosome bands 3p21.31 and 17q11.2, respectively (<http://genome-euro.ucsc.edu/index.html>), the bands identified by G-banding analysis as being recombined by the 3;17-translocation, we decided to investigate further the *SETD2-NF1* fusion transcript using molecular techniques. No other fusions were examined.

RT-PCR with the SETD2-7227F1 and NF1-020-452R1 primer combination amplified a 268 bp cDNA fragment ([Fig. 2B](#f2-or-37-06-3181){ref-type="fig"}). Sanger sequencing showed that it was a *SETD2-NF1* chimeric cDNA fragment with the fusion point identical to that found using FusionCatcher ([Fig. 2C and D](#f2-or-37-06-3181){ref-type="fig"}; [Table I](#tI-or-37-06-3181){ref-type="table"}). In this fusion transcript, the sequence of *SETD2* coding for the last 114 amino acids of the SETD2 protein are replaced by the *NF1* sequence coding for 30 amino acids ([Fig. 2D and E](#f2-or-37-06-3181){ref-type="fig"}).

Interphase FISH analysis confirmed the *SETD2-NF1* fusion. All 100 counted nuclei showed a red signal corresponding to the *SETD2* ([Fig. 3A and C](#f3-or-37-06-3181){ref-type="fig"}), a green signal corresponding to *NF1* ([Fig. 3B and C](#f3-or-37-06-3181){ref-type="fig"}), and a yellow fusion signal corresponding to the *SETD2-NF1* ([Fig. 3C](#f3-or-37-06-3181){ref-type="fig"}).

Discussion
==========

Fusion transcripts of both *NF1* and *SETD2* with various partners have been described in hematologic malignancies as well as solid tumors ([@b20-or-37-06-3181]--[@b22-or-37-06-3181]). However, this is the first time that a fusion between *SETD2* and *NF1* was found.

The *SETD2* gene is ubiquitously expressed and codes for a protein which belongs to a class of huntingtin interacting proteins characterized by WW motifs ([@b23-or-37-06-3181],[@b24-or-37-06-3181]). SETD2 is also a DNA-binding factor that binds the proximal *E1A* promoter of adenovirus serotype 12 ([@b24-or-37-06-3181]). In addition, SETD2 was shown to possess histone H3 lysine 36 (H3-K36) specific HMTase activity, auto-methylation activity, a novel transcriptional activation domain, and association with hyperphosphorylated RNA polymerase II ([@b25-or-37-06-3181]). The SETD2 protein is solely responsible for all H3K36 trimethylation in humans ([@b26-or-37-06-3181]). SETD2 interacts with the Ser2/Ser5 hyperphosphorylated RNA polymerase II during transcriptional elongation via its SRI (Set2 Rpb1 interacting) domain, which explains why H3K36 trimethylation is found in the body of actively transcribed genes ([@b27-or-37-06-3181]). Deletion of the SRI domain in yeast Set2 abolishes H3K36 methylation, which in turn prevents elongation by RNA polymerase II. This suggests that the SRI domain is responsible for coupling transcription to histone methylation by Set2 ([@b28-or-37-06-3181]). It seems that SETD2 serves as a linker between histone H3-K36 methylation and transcriptional regulation in yeast and mammals ([@b25-or-37-06-3181],[@b28-or-37-06-3181]).

Involvement of the *SETD2* gene has been reported in many types of malignancy ([@b29-or-37-06-3181]). Inactivation of *SETD* is common in clear cell renal carcinoma with loss or decrease of H3K36me3 mark ([@b30-or-37-06-3181]), when it is associated with worse prognosis and development of recurrent and/or metastatic disease ([@b31-or-37-06-3181]). Downregulation of *SETD2* at transcriptional and protein levels was observed in breast cancer ([@b32-or-37-06-3181],[@b33-or-37-06-3181]). The expression of *SETD2* was lower in malignant samples, decreased with increasing tumor stage, and was lower in samples from patients who developed metastasis, local recurrence, or died from breast cancer compared to those who were disease-free for \>10 years ([@b32-or-37-06-3181]). *SETD2* mutations were also described in high-grade gliomas and in leukemias ([@b34-or-37-06-3181]--[@b36-or-37-06-3181]). The mutations are either nonsense or frameshift mutations that truncate a portion of the C terminus domain of SETD2. Truncating mutations result in loss of the C terminus SRI domain which is responsible for the recruitment of SETD2 to its target gene locus through binding to the phosphor-C-terminal repeat domain (PCTD) of elongating RNA polymerase II ([@b36-or-37-06-3181]). Recently, genomic disruption of *SETD2* was reported in chronic lymphocytic leukemia and the data suggested that *SETD2* aberrations may be clinically relevant ([@b37-or-37-06-3181]). Patients with *SETD2* abnormalities and wild-type *TP53* and *ATM* had significantly shorter progression-free and overall survival compared with cases with wild-type for all three genes ([@b37-or-37-06-3181]). In malignant mesotheliomas, a combination of the methods array comparative genomic hybridization and targeted next-generation sequencing revealed biallelic *SETD2* inactivation in 9 out of 33 examined tumors ([@b38-or-37-06-3181]). Gene fusions and splice alterations were also reported to be frequent mechanisms for *SETD2* inactivation ([@b39-or-37-06-3181]).

*SETD2* was found to be the most significantly and recurrently mutated gene in type II enteropathy-associated T-cell lymphoma (EATL-II); 86% (13/15) of EATL-II tumors with 20 distinctive mutations ([@b40-or-37-06-3181]). Fourteen of these mutations consisted of premature stop codon, nonsense, frameshift indels or splicing mutations expected to confer critical changes in protein structure. The other six missense mutations occurred in highly conserved residues of functional domains and were predicted to be deleterious with a damaging effect on the protein ([@b40-or-37-06-3181]).

The *NF1* gene spans approximately 280 kbp, has 58 exons (mRNA transcript variant 1, NM_001042492.2) and codes for the cytoplasmatic and multidomain protein neurofibromin ([@b41-or-37-06-3181]). Neurofibromin is a negative regulator of the RAS cellular proliferation pathway ([@b42-or-37-06-3181]--[@b45-or-37-06-3181]). Several other functions of neurofibromin were also reported, among them positive regulation of adenyl cyclase, regulation of cell adhesion and motility, and suppression of epithelial mesenchymal transition ([@b42-or-37-06-3181]--[@b45-or-37-06-3181]). The *NF1* gene is a classical tumor suppressor gene whose inactivation is responsible for the neurofibromatosis type 1 (NF1) tumor predisposition syndrome (<http://omim.org/entry/613113>). Mutations of *NF1* are also linked to juvenile myelomonocytic leukemia (<http://omim.org/entry/607785>) and Watson syndrome (<http://omim.org/entry/193520>). The NF1 syndrome is characterized by the development of multiple neurofibromas, café-au-lait spots, and Lisch nodules ([@b42-or-37-06-3181],[@b45-or-37-06-3181]). Patients with NF1 syndrome are at increased risk to develop malignant peripheral nerve sheath tumors, phaeochromocytoma, leukemia, glioma, rhabdomyosarcoma, and breast cancer ([@b42-or-37-06-3181],[@b45-or-37-06-3181]). Both alleles of *NF1* are inactivated in the tumors in NF1 patients. Mutations in the *NF1* gene may also result in cardiovascular, musculoskeletal, and nervous system anomalies ([@b45-or-37-06-3181],[@b46-or-37-06-3181]).

Splicing in the *NF1* gene is complex and several alternative transcripts were found ([@b47-or-37-06-3181]); altogether 23 according to the ensemble genome browser (<http://www.ensembl.org/Homo_sapiens/Gene/Summary?db=core;g=ENSG00000196712;r=17:31378891-31382106;t=ENST00000422121>). The transcript NF1-020 (ENST00000422121) has three exons and is thought to undergo nonsense mediated decay, a process which detects nonsense mutations and prevents the expression of truncated or erroneous proteins ([@b48-or-37-06-3181]). Thus, the functional significance, if any, of the NF1-020 transcript is unclear.

In the present case, the t(3;17) resulted in a *SETD2-NF1* fusion transcript in which the first 18 exons of *SETD2* (sequence with accession number NM_014159 version 6) are fused to exon 3 of the transcript *NF1-020* (ENST00000422121) ([Fig. 2C and D](#f2-or-37-06-3181){ref-type="fig"}). The fusion transcript would code for a protein in which the last 114 amino acids of SETD2, in other words the entire SRI domain, are replaced by 30 amino acids encoded by the *NF1* sequence ([Fig. 2D and E](#f2-or-37-06-3181){ref-type="fig"}). The result would be similar to that seen with the truncating *SETD2* mutations found in leukemias ([@b36-or-37-06-3181]). Absence of the SRI domain would result in inability to recruit SETD2 to its target gene locus through binding to the phosphor-C-terminal repeat domain of elongating RNA polymerase II and may affect H3K36 methylation. Alternatively, loss of one of two functional *SETD2* alleles might be the crucial factor in tumorigenesis. Whether aberrations of *SETD2* are recurrent and define a specific subgroup of spindle cell tumors, remains to be seen.
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![Pathologic features of the tumor. (A) Macroscopic picture of the tumor surrounded by subcutaneous fatty tissue. (B) Microscopic examination of a haematoxylin and eosin (H&E)-stained slide showing the moderately cellular tumor with spindle cells in a myxoid and fibrous stroma with dilated vessels. (C) Immunohistochemical analysis demonstrating positivity for CD34. (D) Immunohistochemical analysis demonstrating positivity for CD99.](OR-37-06-3181-g00){#f1-or-37-06-3181}

![Cytogenetic and molecular genetic features of the tumor. (A) Partial karyotype showing the der([@b3-or-37-06-3181])t(3;17)(p21;q12) and der([@b17-or-37-06-3181])t(3;17)(p21;q12) together with their normal chromosome homologs; breakpoint positions are indicated by arrows. (B) Amplification of a cDNA fragment (lane 1) using the primers SETD2-7227F1 and NF1-020-452R1. M, 1 kb DNA ladder (GeneRuler, ThermoFisher Scientific). (C) Partial sequence chromatogram of the cDNA fragment showing that exon 18 of *SETD2* (sequence with accession number NM_014159 version 6) is fused to exon 3 of *NF1*-020 (ENST00000422121). (D) Sequence of the amplified cDNA fragment. SETD2-7227F1 and NF1-020-452R1 are shown in boxes. The fusion point 'gc' is double underlined. The open reading frame is also shown. (E) Illustration of the SETD2 protein, the putative SETD2-NF1 chimeric protein, and their functional domains.](OR-37-06-3181-g01){#f2-or-37-06-3181}

![Interphase FISH for the detection of a *SETD2-NF1* fusion gene. (A) The positions of the clones RP11-565B06 (chr3:46962826-47104129) and RP11-380M12 (chr3:47033474-47226748) are indicated in chromosome band 3p21.31. The clones contained the *SETD2* gene and were labeled with red. (B) The positions of the clones RP11-518B17 (chr17:26576215-26749754) and RP11-592F3 (chr17:26705272-26874157) are indicated in chromosome band 17q11.2. The clones contained part of the *NF1* gene and were labeled with green. (C) Interphase FISH showing nucleus with a green signal, a red signal, and a yellow signal. The yellow signal corresponds to the *SETD2-NF1* fusion gene. The fact that there is only one yellow signal indicates that there is no reciprocal fusion.](OR-37-06-3181-g02){#f3-or-37-06-3181}

###### 

Fusion transcripts detected using FusionCatcher.

  5′-Chr    3′-Chr   5′-Partner gene   3′-Partner gene   Fusion description   Fusion sequence
  --------- -------- ----------------- ----------------- -------------------- ----------------------------------------------------------
  17          3      *COL1A1*          *APOD*                                 GCTCCCTCCCACCCAACCAACTTTC\*cccccccccataaagacaaaccaat
    **3**   **17**   ***SETD2***       ***NF1***                              **AACATATGATGAAAACCCCATGAAG\*cactgctcagcacgcaggcatgtga**
    7         3      *COL1A2*          *APOD*                                 CTGGCAACATTGGATTCCCTGGACC\*catcggcaccgtactggatcctggc
  19        19       *ADCK4*           *NUMBL*           readthrough          TCCAGCCTCTCAGTGTGTTGGAGAG\*acggggcgggcaccatgaacaagtt
    1         1      *PEAR1*           *LRRC71*          readthrough          TCCAGGGCCCTGTGTACATAAACTG\*aggagtaccagtgctccggggtcct
    2         3      *IGFBP5*          *APOD*                                 CAGGACTGACCCTCCTTCCTCCAGC\*cacccagccccaagatggtgatgct
  19        19       *CYP4F12*         *CYP4F24P*        pseudogene           ACCGCGATCCTAAAGAGATTGAATG\*gcattatctgcatcatcaacattat
  17          X      *COL1A1*          *TIMP1*                                CTTTCCACCCTCTCTCCACCTGCCT\*ctggcttctggcatcctgttgttgc
    3         3      *DVL3*            *AP2M1*           readthrough          TTCCGCATGGCCATGGGAAACCCCA\*gtctgttctcagagcgatgggccgc
    3         3      *COL7A1*          *UCN2*            readthrough          CGGGTGGTCCAGAGCCAGGGGACAG\*cctgacctcacgatgaccaggtgtg
  11        11       *CTSC*            *RAB38*           readthrough          TTTGTCAGTCCTGTTCGAAACCAAG\*gtcaagaaagatttggaaacatgac
  10        10       *MTG1*            *RP11-108K14.4*   readthrough          CCCTCAACAAACACCAGCGCTTTGG\*gtggaccaggtgctctgaggctggc
  11        11       *LSP1*            *TNNT3*           short distance       CCGGCTCCCTAGGCGTCCCATCTCG\*aaaccacccaccttcaccatgtctg
    1         1      *CTBS*            *GNG5*            readthrough          GCGGGCTCCTTATTATAACTATAAA\*gtttcccaggcagctgcagacttga
  19        19       *GRAMD1A*         *SCN1B*           readthrough          CCTCGGCGGCCACTGCTGGCACGGT\*tgtcctcagcctgcgggggctgcgt
  10        10       *SYNPO2L*         *MYOZ1*           readthrough          CTAAGCGGCAGAGCCGTGCGGACAG\*tgctgcccccacgcctgcccagctc
  19        19       *XRCC1*           *ETHE1*           readthrough          TATGGGGTGGTGCCGCAAGCCTGAA\*gcgttggagaccagggccagccctg
  11        11       *HPX*             *APBB1*           readthrough          TCTTCTCGGCTCCATATCATGGCAG\*gagctgccaaggccatgtctgttcc
  16        16       *LCAT*            *PSMB10*          readthrough          TGAATAAAGACCTTCCTTTGCTACC\*agtacccagtgagcagcacagaggg
    2         2      *SOCS5*           *LINC01119*       short distance       GAGGCCGCCCCGCGCGCCCCAAACG\*atgattccaatgtacagccaatgat
    3         3      *TBC1D23*         *NIT2*            readthrough          GAATAGAAATCTTGGCAATCGAAAG\*ctttccgcttggccctcatccagct
    2         2      *ADCY3*           *PTRHD1*          readthrough          CACGGGGGTCATGGGCAACATTCAG\*gccccagatgagaccaccctaaagg
  19        19       *CADM4*           *ZNF428*          readthrough          GCGCTCTACGTACTTGTGGTCTACG\*catccctctctacctgccaacatcc
  20        20       *CCM2L*           *HCK*             short distance       CCGACTTCAGCTGCTGCAGCTCCTT\*gatggggtgcatgaagtccaagttc
  17        20       *COL1A1*          *CPXM1*                                CCACCCAACCAACTTTCCCCCCAAC\*catcacctgccattgcccacttact
  16        16       *COQ9*            *POLR2C*          readthrough          TGAGACAAGTGCCTGCTGGACAGAG\*gaggccgcagaagacgctcggcagt
    1         1      *EIF4G3*          *HP1BP3*          readthrough          AAAAAGGTGATCATGGAGGAAAAAG\*gttgattcttcaccacactgaaacc
    X         X      *MORF4L2-AS1*     *TMEM31*          readthrough          AGAAGAGTGCAGGAAAGCAAACCAA\*gtgatcactttactgtagaagaaat
    7         7      *RHBDD2*          *POR*             readthrough          AGAGGAGGGCAGCCCAGAGCCGGAA\*tttcatgatcaacatgggagactcc
  14          3      *SERPINA3*        *APOD*                                 CAACAGGCCCTTCCTGATGATCATT\*gtcccttctccagccacccagcccc
    1         1      *VPS45*           *PLEKHO1*         readthrough          GCACCACAGTGCACAACACGAAAAG\*ggacctcaggatggaaaccagcagc
